The Pharma Data
MAY 26, 2023
The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinical supply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialized, ultra-low temperature storage capabilities. With sites in the U.S.,
Pharmaceutical Technology
MAY 24, 2023
By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinical trials holding great hope for the treatment of challenging and uncurable diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 30, 2023
The European Medicines Agency has also approved Efmody for the treatment of congenital adrenal hyperplasia medicine in patients ages 12 years and above in the European Union. Separate from drug development, the Italian company also offers contract manufacturing and clinical supply services.
The Pharma Data
DECEMBER 4, 2021
company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. (AWS), an Amazon.com, Inc.
Pharmaceutical Technology
SEPTEMBER 20, 2022
Clinical packaging and labelling follow stringently controlled procedures and high-standard quality control measures to assure the safety and functionality of investigational medicinal products, during their storage, distribution, and use. Finding the best clinical trial packaging services providers.
The Pharma Data
SEPTEMBER 14, 2020
Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain.
XTalks
JUNE 16, 2023
Concerningly, the survey also revealed that only 40 percent of the surveyed NCCN cancer centers received any indication from manufacturers or suppliers about when carboplatin or cisplatin would be readily available again. Medicines for Europe said the supply issues were evidence of the damaging effects of European cost-containment measures.
Expert insights. Personalized for you.
52 
Let's personalize your content